PET Scan: Nuclear Medicine Imaging in Myositis
Purpose of Review
Positron emission tomography (PET) combined with computed tomography (CT) has proven useful as a cancer screening technique in patients with inflammatory myopathy, mainly dermatomyositis. In this review, we focus on advances in this direction and other potential applications of PET/CT in patients with inflammatory myopathy.
Cancer screening by PET/CT seems suitable and cost-effective in patients with myositis. It has also shown value as a hybrid technique for diagnosing myositis versus controls and could be of interest for differentiating between polymyositis and sporadic inclusion body myositis. Quantification of muscle activity by PET/CT seems reliable. Preliminary data suggest that it could also be used to diagnose and measure the activity of the disease in the lung.
PET/CT should be in the toolbox of physicians managing patients with myositis. The multiple applications of PET/CT include its value for cancer screening, measuring the activity of the disease in muscle, and helping to differentiate between myositis phenotypes. The possibility to diagnose and monitor inflammatory lung activity remains to be demonstrated in well-designed studies.
KeywordsPET/CT Myositis Malignancy Activity Dermatomyositis Sporadic inclusion body myositis
This work was supported by the Instituto de Salud Carlos III and the European Regional Development Fund (ERDF) (grant number PI15/02100).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 14.• Kundrick A, Kirby J, Ba D, Leslie D, Olsen N, Foulke G. Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. Semin Arthritis Rheum. 2018;49:140–4. https://doi.org/10.1016/j.semarthrit.2018.10.021. This study states that PET/CT whole body may be expensive for insurance companies but not for the patients, opening the door to more generalised implementation of PET/CT for dermatomyositis cancer screening in countries where this test is not available through publically-funded health resources. CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118–57.CrossRefGoogle Scholar
- 18.Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2017;76:681–7.PubMedCrossRefPubMedCentralGoogle Scholar
- 23.Tanaka S, Ikeda K, Uchiyama K, Iwamoto T, Sanayama Y, Okubo A, et al. [18F] FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2013;52:1271–8.CrossRefGoogle Scholar
- 26.•• Matuszak J, Blondet C, Hubelé F, Gottenberg JE, Sibilia J, Bund C, et al. Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activityRheumatology (Oxford). 2019. https://doi.org/10.1093/rheumatology/kez040 This is a well conducted study which demonstrates that PET/CT could be useful for monitoring muscle disease activity. The method that they used to measure muscle activity showed an excellent reliability and validity. CrossRefGoogle Scholar
- 27.Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64:1602–10.PubMedCrossRefPubMedCentralGoogle Scholar
- 28.Trallero-Araguás E, Grau-Junyent JM, Labirua-Iturburu A, García-Hernández FJ, Monteagudo-Jiménez M, Fraile-Rodriguez G, et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum. 2016;46:225–31.PubMedCrossRefPubMedCentralGoogle Scholar
- 30.Motegi SI, Fujiwara C, Sekiguchi A, Hara K, Yamaguchi K, Maeno T, et al. Clinical value of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J Dermatol. 2019;46:213–8.PubMedCrossRefPubMedCentralGoogle Scholar
- 34.•• Li Y, Zhou Y, Wang Q. Multiple values of (18)F-FDG PET/CT in idiopathic inflammatory myopathy. Clin Rheumatol. 2017;36:2297–305 This study demonstrates the multiple values of PET/TC in patients with myositis by detecting malignancies, assessing muscle activity, determining interstitial lung activity, and predicting rapidly-progressive interstitial lung disease. PubMedCrossRefPubMedCentralGoogle Scholar
- 41.•• Lilleker JB, Hodgson R, Roberts M, Herholz K, Howard J, Hinz R, et al. [18F] Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann Rheum Dis. 2019 Feb 13. https://doi.org/10.1136/annrheumdis-2018-214644 [18F] florbetapir positron emission tomography can detect tissue deposits of amyloid. In this study the authors suggest that this technique may allow to differentiate inclusion body myositis from polymyositis. PubMedPubMedCentralCrossRefGoogle Scholar